Targeted chemotherapy against intraperitoneally disseminated colon carcinoma using a cationized gelatin-conjugated HVJ envelope vector

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 1021-1028

  Mima, Hidetoshi ^a,c   Yamamoto, Seiji ^a   Ito, Makoto ^a   Tomoshige, Ryuji ^b   Tabata, Yasuhiko ^b   Tamai, Katsuto ^a   Kaneda, Yasufumi ^a,d  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKUSHIMA   (Japan)

^d OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CATIONIZED GELATIN HEMAGGLUTINATING VIRUS OF JAPAN ENVELOPE; LUCIFERASE; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; COLON CARCINOMA; CONTROLLED STUDY; DISSEMINATED CANCER; GENE EXPRESSION; GENE TARGETING; GENETIC TRANSDUCTION; IN VIVO STUDY; MOUSE; NONHUMAN; PERITONEUM CANCER; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS ENVELOPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLEOMYCIN; CATTLE; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; ENDOCYTOSIS; MALE; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; SENDAI VIRUS;

EID: 33646587663     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0352     Document Type: Article

References (41)

1. McMillan TJ, Hart IR. Can cancer chemotherapy enhance the malignant behavior of tumours? Cancer Metastasis Rev 1987;6:503-19.
2. Steinman RM, Mellman I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 2004;305:197-200.
3. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
4. Pawelec G. Immunotherapy and immunoselection: tumour escape as the final hurdle. FEBS Lett 2004;567:63-6.
5. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 2004;53:844-54.
6. Gardini A, Ercolani G, Riccobon A, et al. Adjuvant, adoptive immunotherapy with tumor infiltrating lymphocytes plus interleukin-2 after radical hepatic resection for colorectal liver metastases: 5-year analysis. J Surg Oncol 2004;87:46-52.
7. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J Natl Cancer Inst 2004;96:1128-32.
8. Alen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
9. Kaneda Y. Biological barriers to gene transfer. In: Amiji MM, editor. Polymeric gene delivery principles and application. Washington (DC): CRC Press; 2005. p. 29-41.
10. Wattiaux R, Laurent N, Wattiaux-De Coninck S, Jadot M. Endosomes, lysosomes: their implication in gene transfer. Adv Drug Deliv Rev 2000;41:201-8.
11. Flint SJ, Enquist LW, Krug RM, Racaniello VR, Skalka AM, editors. Principles of virology. Washington (DC): ASM Press; 2000.
12. Seth P. Mechanism of adenovirus-mediated endosome lysis: role of the intact adenovirus capsid structure. Biochem Biophys Res Commun 1994;205:1318-24.
13. Wagner E, Zatloukal K, Cotten M, et al. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci U S A 1992;89:6099-103.
14. Maeda T, Ohnishi S. Activation of influenza virus by acidic media causes hemolysis and fusion of erythrocytes. FEBS Lett 1980;122:283-7.
15. Marsh M, Bolzau E, Helenius A. Penetration of Semliki Forest virus from acidic prelysosomal vacuoles. Cell 1983;32:931-40.
16. Blumenthal R, Bali-Puri A, Walter A, Covell D, Eidelman O. pH-dependent fusion of vesicular stomatitis virus with Vero cells. Measurement by dequenching of octadecyl rhodamine fluorescence. J Biol Chem 1987;262:13614-9.
17. Okada Y. Sendai virus-induced cell fusion. In: Duzgunes N, editor. Methods in enzymology. Vol. 221. San Diego: Academic Press Inc.; 1993. p. 18-41.
18. McClure MO, Sommerfelt MA, Marsh M, Weiss RA. The pH independence of mammalian retrovirus infection. J Gen Virol 1990;71:767-73.
19. Wagner E, Plank C, Zatloukal K, Cotten M, Birnstiel ML. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: toward a synthetic virus-like gene-transfer vehicle. Proc Natl Acad Sci U S A 1992;89:7934-8.
20. Saeki Y, Matsumoto N, Nakano Y, Mori M, Awai K, Kaneda Y. Development and characterization of cationic liposomes conjugated with HVJ (Sendai virus): reciprocal effect of cationic lipid for in vitro and in vivo gene transfer. Hum Gene Ther 1997;8:2133-41.
21. Kaneda Y, Saeki Y, Morishita R. Gene therapy using HVJ-liposomes: the best of both worlds? Mol Med Today 1999;5:298-303.
22. Kaneda Y, Nakajima T, Nishikawa T, et al. Hemagglutinating virus of Japan (HVJ) envelope vector as a versatile gene delivery system. Mol Ther 2002;6:219-26.
23. Kaneda Y, Yamamoto S, Nakajima T. HVJ envelope vector and its application to gene therapy. In: Huang L, Hung M-C, Wagner E, editors. Non-viral vectors for gene therapy. San Diego: Elsevier; 2005. p. 307-32.
24. Mima H, Tomoshige R, Kanamori T, et al. Biocompatible polymer enhances the in vitro and in vivo transfection efficiency of HVJ envelope vector. J Gene Med 2005;7:888-97.
25. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Ultrasound enhancement of in vitro transfection of plasmid DNA by a cationized gelatin. J Drug Target 2002;10:193-204.
26. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Tumor targeting of gene expression through metal-coordinated conjugation with dextran. J Control Release 2003;88:297-312.
27. Hosseinkhani H, Aoyama T, Ogawa O, Tabata Y. Liver targeting of plasmid DNA by pullulan conjugation based on metal coordination. J Control Release 2002;83:287-302.
28. Shpetner H, Joly M, Hartley D, Corvera S. Potential sites of PI-3 kinase function in the endocytic pathway revealed by the PI-3 kinase inhibitor, wortmannin. J Cell Biol 1996;132:595-605.
29. Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. Gen Pharmacol 1996;27:745-8.
30. Miyata T, Yamamoto S, Sakamoto K, Morishita R, Kaneda Y. Novel immunotherapy for peritoneal dissemination of murine colon cancer with macrophage inflammatory protein-1β mediated by a tumor-specific vector, HVJ-cationic liposomes. Cancer Gene Ther 2001;8:852-60.
31. Fujita F, Yamashita-Futsuki I, Eguchi S, et al. Inactivation of porcine endogenous retrovirus by human serum as a function of complement activated through the classical pathway. Hepatol Res 2003;26:106-13.
32. Okada H, Wu X, Okada N. Complement-mediated cytolysis and azidothymidine are synergistic in HIV-1 suppression. Int Immunol 1998;10:91-5.
33. Hirano T, Fujimoto J, Ueki T, et al. Persistent gene expression in rat liver in vivo by repetitive transfections using HVJ-liposome. Gene Ther 1998;5:459-64.
34. Buttiglieri S, Galetto A, Forno S, DeAndrea M, Matera L. Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer 2003;106:516-20.
35. Cao ZA, Daniel D, Hanahan D. Sub-lethal radiation enhances anti-tumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2002;2:11.
36. Pavlovic J, Nawrath M, Tu R, Heinicke T, Moelling K. Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras(G12V). Gene Ther 1996;3:635-43.
37. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:1-7.
38. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol 2005;42:859-67.
39. Lopez CB, Garcia-Saraste A, Williams BR, Moran TM. Type I interferon induction pathway, but not released interferon, participates in the maturation of dendritic cells induced by negative-strand RNA viruses. J Infect Dis 2003;187:1126-36.
40. Lopez CB, Moltedo B, Alexopoulou L, Flavell RA, Moran TM. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA virus. J Immunol 2004;173:6882-9.
41. Ito T, Amakawa R, Inaba M, et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004;172:4253-9.